Scope
The joint AGA–ACG guideline evaluates medicines for chronic idiopathic constipation in adults. It supports a stepwise, shared choice of affordable over-the-counter options and prescription agents when response is inadequate. Strong recommendations and conditional suggestions are distinguished; the document does not provide a diagnostic pathway for all causes of constipation.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Confirm that the pharmacological pathway applies
- These recommendations concern adult chronic idiopathic constipation. The evidence review excludes IBS with constipation, opioid-induced constipation and constipation caused by another medical condition; malignancy and pregnancy are not specifically addressed. [1]
- Choose treatment jointly with the patient, considering preferences, cost and availability. Dietary and behavioural measures commonly precede medicines, including dietary fibre, fluid intake and exercise. [1]
Choose an appropriate initial or over-the-counter option
- Suggest fibre supplementation, particularly when dietary intake is low; this is conditional with low-certainty evidence. Psyllium has the clearest evidence among the studied fibres. Encourage hydration and discuss flatulence. [1]
- Recommend polyethylene glycol for adult CIC, with moderate-certainty evidence. A fibre trial can precede it in mild constipation or be combined with it. Benefit has persisted over 6 months in studies; distension, loose stool, flatulence and nausea can occur. [1]
- Suggest magnesium oxide conditionally on very-low-certainty evidence. Start low and increase if needed. Avoid it in renal insufficiency because of hypermagnesaemia risk. [1]
- For adults who fail or cannot tolerate over-the-counter treatments, suggest lactulose conditionally on very-low-certainty evidence. Dose-related bloating and flatulence commonly limit use. [1]
- Recommend bisacodyl or sodium picosulfate for short-term or rescue use, with moderate-certainty evidence. Short term means daily use for at most 4 weeks; longer-term tolerance and safety data are limited. Begin low and titrate to reduce cramping, pain and diarrhoea. [1]
- Bisacodyl and sodium picosulfate are contraindicated with ileus, intestinal obstruction, severe dehydration or acute inflammatory bowel conditions. [1]
- Suggest senna conditionally on low-certainty evidence. Start below the high doses used in trials and increase if needed; abdominal pain and cramping may occur. Longer-term use is probably appropriate, but tolerance and adverse-effect evidence remains limited. [1]
Escalate after inadequate over-the-counter response
- Suggest lubiprostone for adults not responding to over-the-counter agents, conditionally on low-certainty evidence. It can replace or supplement these agents. Take with food and water to reduce dose-related nausea; avoid use with known or suspected mechanical gastrointestinal obstruction. [1]
- Recommend linaclotide after inadequate response to over-the-counter agents, with moderate-certainty evidence. It may replace or supplement them; diarrhoea can require discontinuation. Take without food at least 30 minutes before the first meal, and avoid use with known or suspected mechanical gastrointestinal obstruction. [1]
- Recommend plecanatide after inadequate over-the-counter response, with moderate-certainty evidence. It can replace or supplement those agents. The trials lasted 12 weeks; diarrhoea may lead to stopping treatment. [1]
- Recommend prucalopride after inadequate over-the-counter response, with moderate-certainty evidence. It can replace or supplement those agents; headache, abdominal pain, nausea and diarrhoea are possible adverse effects. [1]
- The guideline lists prucalopride 2 mg once daily for adults, reduced to 1 mg daily when creatinine clearance is below 30 mL/min. It is contraindicated in intestinal perforation or obstruction, Crohn disease, ulcerative colitis, and toxic megacolon or megarectum. [1]
- With prucalopride, counsel about unusual changes in mood or behaviour and suicidal thoughts. The label warns about these events, although causation remains uncertain. [1]
Limitations and use
- This guideline addresses adult idiopathic constipation medicines, not the diagnostic work-up, defecatory disorders, secondary constipation, pregnancy, paediatric disease or an acute bowel obstruction pathway.
- The recommendations compare drugs with no intervention or placebo and do not establish a direct efficacy ranking between all agents. Most trials were relatively short.
- This is not a complete prescribing monograph. Confirm product availability, current regional labelling, contraindications and organ-function adjustments before use; most exact doses are deliberately not reproduced here.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
Publication details
- Issuing organisation
- ACG
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.